CytomX Therapeutics, Inc. (CTMX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, CytomX Therapeutics reported revenue of $76.2M, down 44.8% from $138.1M the year before. Net income was -$17.4M (a -22.8% net margin), or -$0.13 per diluted share. Operating margin was -29.3%. Operating activities generated -$75.6M of cash, leaving -$75.8M of free cash flow. At fiscal year end, CytomX Therapeutics held $151.6M in total assets against $52.6M in total liabilities, including $12.7M of cash and equivalents.
Open the full interactive CytomX Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
CytomX Therapeutics Key Stats
| Share Price | $2.33 |
|---|---|
| Market Cap | $509.0M |
| Revenue YoY Growth | -44.8% |
| 52-Week Range | $2.33 – $6.75 |
| Shares Outstanding | 218.9 million (basic, 2026 Q2) |
CytomX Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $100.4M | $69.6M | $53.2M | $101.2M | $138.1M | $76.2M |
| Operating Income | -$48.6M | -$83.8M | -$101.3M | -$6.5M | $25.0M | -$22.4M |
| Pre-Tax Income | -$46.8M | -$83.6M | -$99.3M | $3.3M | $32.1M | -$17.1M |
| Income Tax | -$13.9M | $0 | $0 | $3.9M | $224,000 | $238,000 |
| Net Income | -$32.9M | -$83.6M | -$99.3M | -$569,000 | $31.9M | -$17.4M |
| Diluted EPS | -$0.71 | -$1.30 | -$1.51 | -$0.01 | $0.38 | -$0.13 |
CytomX Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $6.0M | $663,000 | $10.3M | $1.4M |
| Net Income | -$14.2M | -$26.5M | -$18.2M | -$20.7M |
| Diluted EPS | -$0.09 | -$0.19 | -$0.10 | -$0.09 |
CytomX Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $191.9M | $205.5M | $193.7M | $17.2M | $38.1M | $12.7M |
| Current Assets | $324.0M | $310.3M | $237.1M | $182.9M | $107.3M | $143.9M |
| Total Assets | $358.7M | $339.4M | $260.9M | $201.8M | $120.5M | $151.6M |
| Current Liabilities | $100.9M | $106.3M | $152.6M | $155.9M | $85.8M | $46.6M |
| Total Liabilities | $308.9M | $250.0M | $346.6M | $249.2M | $121.0M | $52.6M |
| Shareholders' Equity | $49.8M | $89.4M | -$85.8M | -$47.4M | -$456,000 | $99.0M |
CytomX Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $5.3M | -$119.0M | -$110.8M | -$56.0M | -$86.2M | -$75.6M |
| Cash From Investing | -$18.7M | $22.5M | $98.3M | -$150.7M | $99.7M | -$59.7M |
| Cash From Financing | $16.9M | $110.2M | $648,000 | $30.2M | $7.5M | $110.4M |
| Free Cash Flow | $3.0M | -$120.6M | -$112.5M | -$56.9M | -$86.5M | -$75.8M |
Figures from CytomX Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full CytomX Therapeutics financials page for every line item.
CytomX Therapeutics Company Profile
| Ticker | CTMX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001501989 |
Frequently Asked Questions
What was CytomX Therapeutics' revenue in fiscal 2025?
CytomX Therapeutics (CTMX) reported revenue of $76.2M for fiscal 2025.
What is CytomX Therapeutics' annual revenue history?
CytomX Therapeutics' annual revenue by fiscal year: 2020: $100.4M; 2021: $69.6M; 2022: $53.2M; 2023: $101.2M; 2024: $138.1M; 2025: $76.2M.
What was CytomX Therapeutics' net income in fiscal 2025?
CytomX Therapeutics reported net income of -$17.4M for fiscal 2025.
What was CytomX Therapeutics' earnings per share (EPS) in fiscal 2025?
CytomX Therapeutics' diluted EPS was -$0.13 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did CytomX Therapeutics generate in fiscal 2025?
CytomX Therapeutics generated -$75.8M of free cash flow in fiscal 2025.
What was CytomX Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), CytomX Therapeutics reported revenue of $1.4M.
How many shares of CytomX Therapeutics are outstanding?
CytomX Therapeutics reported a weighted average of 218.9 million basic shares outstanding in 2026 Q2.
What is CytomX Therapeutics' market cap?
Based on its latest closing price, CytomX Therapeutics (CTMX) has a market capitalization of about $509.0M.
When does CytomX Therapeutics' fiscal year end?
CytomX Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is CytomX Therapeutics headquartered?
CytomX Therapeutics lists its business address in South San Francisco, California in its SEC filings.